Safety and Immunogenicity of an AMA-1 Malaria Vaccine in Malian Adults: Results of a Phase 1 Randomized Controlled Trial
2008

Safety and Immunogenicity of an AMA-1 Malaria Vaccine in Malian Adults

Sample size: 60 publication 10 minutes Evidence: moderate

Author Information

Author(s): Thera Mahamadou A., Doumbo Ogobara K., Coulibaly Drissa, Diallo Dapa A., Kone Abdoulaye K., Guindo Ando B., Traore Karim, Dicko Alassane, Sagara Issaka, Sissoko Mahamadou S., Baby Mounirou, Sissoko Mady, Diarra Issa, Niangaly Amadou, Dolo Amagana, Daou Modibo, Diawara Sory I., Heppner D. Gray, Stewart V. Ann, Angov Evelina, Bergmann-Leitner Elke S., Lanar David E., Dutta Sheetij, Soisson Lorraine, Diggs Carter L., Leach Amanda, Owusu Alex, Dubois Marie-Claude, Cohen Joe, Nixon Jason N., Gregson Aric, Takala Shannon L., Lyke Kirsten E., Plowe Christopher V.

Primary Institution: Malaria Research and Training Center, University of Bamako, Bamako, Mali

Hypothesis

The study aimed to evaluate the safety, reactogenicity, and immunogenicity of the AMA-1-based malaria vaccine FMP2.1/AS02A in adults exposed to seasonal malaria.

Conclusion

The FMP2.1/AS02A vaccine had a good safety profile, was well-tolerated, and was highly immunogenic in malaria-exposed adults.

Supporting Evidence

  • The vaccine induced significant increases in anti-AMA-1 antibodies, peaking at nearly 5-fold and more than 6-fold higher than baseline in the half-dose and full-dose groups, respectively.
  • Transient local pain and swelling were common and more frequent in both malaria vaccine dosage groups than in the comparator group.
  • No serious adverse events occurred during the study.
  • Participants receiving the full dose of the malaria vaccine had significantly greater mean antibody responses compared to those receiving the comparator vaccine.
  • Immunization with both doses of the malaria vaccine was followed by significant elevations in anti-AMA-1 antibodies.
  • Local reactions were more frequent in both malaria vaccine groups than in the comparator group.
  • All local solicited symptoms resolved without sequelae during the 8-day post-immunization periods.
  • Longitudinal analyses suggested a dose-related antibody response with higher responses in the full-dose group.

Takeaway

Researchers tested a malaria vaccine on adults in Mali and found it was safe and helped their bodies make strong defenses against malaria.

Methodology

A phase 1 double blind randomized controlled dose escalation trial was conducted with 60 healthy, malaria-experienced adults who received either a malaria vaccine or a rabies vaccine.

Potential Biases

Potential bias due to the open-label nature of the trial and the small sample size.

Limitations

The study was not powered to detect differences between groups and had a small sample size.

Participant Demographics

Participants were healthy adults aged 18–55 years, with a mean age of 28 years, and included 11 females.

Statistical Information

P-Value

0.050

Confidence Interval

95% CI for geometric mean antibody titers

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1371/journal.pone.0001465

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication